Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

1.37
+0.01000.74%
Post-market: 1.410.0400+2.92%16:05 EDT
Volume:76.69K
Turnover:104.24K
Market Cap:19.58M
PE:-0.75
High:1.39
Open:1.37
Low:1.32
Close:1.36
52wk High:9.19
52wk Low:1.27
Shares:14.29M
Float Shares:12.74M
Volume Ratio:0.77
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8300
EPS(LYR):-0.4770
ROE:-2543.13%
ROA:-44.74%
PB:6.85
PE(LYR):-2.87

Loading ...

On National Viagra Day, Women Finally Claim Their Turn:

GlobeNewswire
·
Yesterday

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

GlobeNewswire
·
Mar 20

Daré Bioscience completes Regulation A sale of 43,050 investor units at USD 5 each

Reuters
·
Mar 18

Dare Bioscience receives NIH funding award notice for DARE-PTB1

TIPRANKS
·
Mar 16

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

GlobeNewswire
·
Mar 16

FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study

Reuters
·
Mar 12

FDA clears Daré Bioscience IND for DARE-HPV Phase 2 study

Reuters
·
Feb 23

DarÉ Bioscience Announces FDA Clearance of Ind for Phase 2 Clinical Study of Dare-Hpv, a Potential Treatment for Persistent High-Risk Hpv Infection, the Most Common Cause of Cervical Cancer

THOMSON REUTERS
·
Feb 23

Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women

GlobeNewswire
·
Feb 11

Dare Bioscience Unveils Evidence-Backed Sildenafil Cream for Female Arousal

Reuters
·
Dec 10, 2025

Dare Bioscience Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 02, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02, 2025

BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal

Reuters
·
Dec 01, 2025

Dare Bioscience Secures Gates Foundation Grant for Ovaprene Phase 3 Trial

Reuters
·
Dec 01, 2025

Dare Bioscience Inc - Termination Effective February 2026, DarÉ Gains Full Control of Ovaprene

THOMSON REUTERS
·
Dec 01, 2025

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

GlobeNewswire
·
Dec 01, 2025

Press Release: Daré Bioscience Receives $3.6 Million in Additional Grant Funding

Dow Jones
·
Nov 24, 2025

Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate

Benzinga
·
Nov 14, 2025

Dare Bioscience Reports Q3 2025 Results and Plans December Launch of Sildenafil Cream

Reuters
·
Nov 14, 2025

Dare Bioscience to host webinar on the DARE to PLAY

TIPRANKS
·
Nov 11, 2025